Collaboration agreements - Merck Immunosythen Agreement (Details) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
|
Dec. 31, 2022
USD ($)
target
performanceObligation
license
|
Sep. 30, 2024
USD ($)
|
Sep. 30, 2023
USD ($)
|
Sep. 30, 2024
USD ($)
|
Sep. 30, 2023
USD ($)
|
Dec. 31, 2023
USD ($)
|
|
| Collaboration agreements | ||||||
| Collaboration revenue | $ 12,598 | $ 7,698 | $ 24,136 | $ 26,154 | ||
| Deferred revenue | $ 147,653 | 115,237 | 133,096 | 115,237 | 133,096 | $ 125,314 |
| 2022 Merck Research Collaboration & License Agreement | ||||||
| Collaboration agreements | ||||||
| Number of targets designated | target | 2 | |||||
| Upfront payment received | $ 30,000 | |||||
| Number of licenses | license | 2 | |||||
| Performance obligations identified | performanceObligation | 4 | |||||
| Collaboration revenue | 3,400 | $ 2,300 | 6,600 | $ 7,900 | ||
| Receivable from customer | 1,000 | 1,000 | ||||
| Deferred revenue | $ 14,600 | $ 14,600 | $ 20,200 | |||
| X | ||||||||||
- Definition The number of licenses granted to a collaborator No definition available.
|
| X | ||||||||||
- Definition Number of targets designated as of balance sheet date. No definition available.
|
| X | ||||||||||
- Definition The number of material performance obligations identified under a collaboration arrangements related to designated targets No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|